SEC Filing Summary: Acasti Pharma Inc. Form 10-K
Entity and period: The supplied filing is Acasti Pharma Inc.’s Form 10-K, not a filing by Grace Therapeutics, Inc. It covers the fiscal year ended March 31, 2024; it does not provide standalone fiscal Q4 results. Amounts are in U.S. dollars unless stated otherwise.
Business context and reporting period
Acasti is a clinical-stage biopharmaceutical company developing reformulated drugs for rare and orphan diseases, using the FDA’s potential 505(b)(2) pathway. Its lead candidate, GTX-104, is an intravenous nimodipine formulation for patients with aneurysmal subarachnoid hemorrhage (aSAH). GTX-102 and GTX-101 were deprioritized in favor of GTX-104. The company reported no product-sales revenue and remains dependent on external financing.
Financial and operating metrics
| Metric | FY ended March 31, 2024 | FY ended March 31, 2023 |
|---|---|---|
| Revenue | No product-sales revenue reported | No product-sales revenue reported |
| Net loss | $12.9 million; $1.35 per share | $42.4 million; $5.71 per share |
| Loss from operating activities | $12.9 million | $52.2 million |
| Research and development expense | $4.7 million | $10.0 million |
| General and administrative expense | $6.4 million | $7.6 million |
| Cash used in operating activities | $12.3 million | $15.9 million |
| Cash and cash equivalents at year-end | $23.0 million | $27.9 million |
At March 31, 2024, current assets were $24.0 million and current liabilities were $1.7 million; total assets were $73.3 million and shareholders’ equity was $61.7 million. No interest-bearing borrowings are shown in the balance sheet. Other liabilities included $4.4 million of derivative warrant liabilities and $5.5 million of deferred tax liabilities. The filing does not present a meaningful operating margin because the company has no product-sales revenue.
Cash declined $4.9 million year over year. Investing activities provided $0.1 million, while financing activities provided $7.4 million, primarily from a September 2023 private placement. The company reported $6.0 million of CRO commitments for the next 12 months and no CMO commitments at year-end.
Material changes versus the prior comparable period
- Net loss narrowed by $29.6 million, principally because FY2023 included $33.5 million of aggregate intangible-asset and goodwill impairment charges and a related tax benefit. FY2024 had no impairment charge.
- Operating expenses fell as Acasti restructured and concentrated resources on GTX-104. R&D expense declined by $5.3 million; G&A declined by $1.2 million. FY2024 also included $1.5 million of restructuring costs.
- Operating cash use improved by $3.6 million, mainly reflecting lower development spending and staffing costs, partly offset by restructuring costs, higher professional fees and operating working-capital movements.
- In September 2023, the company raised approximately $7.3 million net through a private placement, issuing common shares and pre-funded warrants alongside common warrants. The common warrants are recorded as derivative liabilities and may create future dilution.
- Acasti completed a 1-for-6 reverse stock split in July 2023 to regain Nasdaq minimum-bid-price compliance. Ernst & Young was dismissed in December 2023 and KPMG LLP became the auditor for FY2024.
Guidance, outlook, risks and unusual items
- STRIVE-ON, Acasti’s open-label, randomized Phase 3 safety trial comparing GTX-104 with oral nimodipine, began enrolling in October 2023 and was ongoing at the filing date. The company anticipated a potential NDA submission in the first half of calendar 2025, subject to trial progress and regulatory review.
- Management said existing cash and cash equivalents were expected to fund operations into the second calendar quarter of 2026. Additional capital will be needed beyond that period; financing may be dilutive or unavailable on acceptable terms.
- GTX-102 and GTX-101 development is deferred, potentially for at least three years from April 2023, pending additional funding or strategic partnerships. The company may license or sell these assets.
- Key risks include dependence on GTX-104; uncertain clinical outcomes, trial enrollment and FDA approval; reliance on third-party CROs and manufacturers; 505(b)(2) pathway and intellectual-property litigation risks; commercialization, pricing and reimbursement uncertainty; and the need for further financing. GTX-104’s Phase 3 study is intended to be the final clinical step, but approval is not assured.
- Intangible assets and goodwill totaled $49.3 million, about 67% of total assets, and their valuations rely on uncertain development, approval and sales assumptions. Management disclosed that lower projected sales could trigger impairment; no FY2024 impairment was recorded.
- Aker BioMarine’s former CaPre supply dispute was settled in October 2023. Acasti transferred CaPre-related raw material, equipment, data and intellectual property to Aker BioMarine in exchange for a release of claims; no liability was recorded at March 31, 2024.
- Management reported effective disclosure controls and internal control over financial reporting as of March 31, 2024. KPMG issued an unmodified audit opinion and reported no critical audit matters; it did not audit or attest to internal-control effectiveness. No legal proceeding was identified as likely to have a material adverse effect, though the filing notes outcomes can be uncertain.
Important facts for investors to verify
- STRIVE-ON enrollment, safety results, timeline and whether the FDA continues to accept the planned 505(b)(2) pathway and scientific bridge.
- Whether the stated cash runway remains achievable given actual spending, the $6.0 million CRO commitment and the timing and terms of any new financing.
- Potential dilution from the pre-funded warrants, common warrants and outstanding stock options; common warrants cover up to 2,536,391 shares and have a $3.003 exercise price.
- Key valuation assumptions supporting the $49.3 million of intangible assets and goodwill, and whether changes in trial prospects or sales forecasts could cause future impairment.
- Status and potential value of GTX-102 and GTX-101, and any partnership, licensing or sale developments.
- Whether government research tax-credit receivables are realized and how Acasti’s disclosed PFIC risk may affect U.S. shareholders’ tax treatment.